靶向套细胞淋巴瘤的免疫微环境：对现有和新兴疗法的影响。
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
机构信息
Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Leuk Lymphoma. 2022 Nov;63(11):2515-2527. doi: 10.1080/10428194.2022.2086244. Epub 2022 Jun 15.
Abstract
Mantle cell lymphoma (MCL) is a morphologically and phenotypically heterogeneous subtype of non-Hodgkin lymphoma, and has historically been associated with poor outcomes. However, recent advances in our understanding of this disease have yielded new targeted and immune-based therapies with promising activity. Immune-based therapies such as monoclonal antibodies, immunomodulators, and CAR T cells have significantly improved outcomes and are now standard of care in MCL. In this review, we describe our current understanding of the immune microenvironment of MCL, discuss current immunotherapeutic approaches, and highlight promising novel immune-based therapies and combination therapies that may further improve outcomes for patients with MCL.
摘要
套细胞淋巴瘤（MCL）是一种形态学和表型上具有异质性的非霍奇金淋巴瘤亚型，其历史上与不良预后相关。然而，近年来我们对这种疾病的认识的进展带来了新的靶向和免疫为基础的治疗方法，具有良好的疗效。免疫为基础的治疗方法，如单克隆抗体、免疫调节剂和 CAR T 细胞，显著改善了预后，现在是 MCL 的标准治疗方法。在这篇综述中，我们描述了我们目前对 MCL 的免疫微环境的理解，讨论了当前的免疫治疗方法，并强调了有前途的新型免疫为基础的治疗方法和联合治疗方法，这可能进一步改善 MCL 患者的预后。
相似文献
1
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.靶向套细胞淋巴瘤的免疫微环境：对现有和新兴疗法的影响。
Leuk Lymphoma. 2022 Nov;63(11):2515-2527. doi: 10.1080/10428194.2022.2086244. Epub 2022 Jun 15.
2
Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.针对套细胞淋巴瘤治疗中肿瘤细胞微环境的靶向治疗原理。
Leuk Lymphoma. 2018 May;59(5):1064-1072. doi: 10.1080/10428194.2017.1357177. Epub 2017 Jul 31.
3
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.套细胞淋巴瘤的微环境：细胞和分子途径及新兴的靶向治疗。
Semin Cancer Biol. 2011 Nov;21(5):308-12. doi: 10.1016/j.semcancer.2011.09.006. Epub 2011 Sep 18.
4
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.复发/难治性套细胞淋巴瘤治疗模式的转变。
Leuk Res. 2023 Nov;134:107385. doi: 10.1016/j.leukres.2023.107385. Epub 2023 Sep 1.
5
Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.套细胞淋巴瘤：风险适应性治疗及复发疾病治疗的作用
Curr Oncol Rep. 2022 Oct;24(10):1313-1326. doi: 10.1007/s11912-022-01297-x. Epub 2022 May 31.
6
Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.套细胞淋巴瘤的新型疗法：通向无化疗策略之路
Oncology (Williston Park). 2013 Oct;27 Suppl 2:8-12.
7
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.套细胞淋巴瘤研究的最新进展与未来方向：2016年套细胞淋巴瘤联盟研讨会报告
Leuk Lymphoma. 2017 Jul;58(7):1561-1569. doi: 10.1080/10428194.2017.1283036. Epub 2017 Jan 31.
8
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.新型药物时代的高危套细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):8-18. doi: 10.1007/s11899-021-00605-9. Epub 2021 Jan 28.
9
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.SOHO最新技术进展与后续问题 | 接受布鲁顿酪氨酸激酶（BTK）抑制剂治疗后病情进展的套细胞淋巴瘤患者的免疫治疗选择
Clin Lymphoma Myeloma Leuk. 2023 Dec;23(12):861-865. doi: 10.1016/j.clml.2023.08.011. Epub 2023 Aug 14.
10
The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.抗体药物偶联物 VLS-101 靶向 ROR1 在 CAR T 耐药套细胞淋巴瘤中有效。
J Hematol Oncol. 2021 Aug 28;14(1):132. doi: 10.1186/s13045-021-01143-w.
引用本文的文献
1
Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway.安罗替尼通过PI3K/AKT/mTOR通路抑制套细胞淋巴瘤增殖并诱导凋亡。
Curr Mol Med. 2025;25(4):472-484. doi: 10.2174/0115665240284638240408081133.
本文引用的文献
1
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
2
Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.套细胞淋巴瘤将肿瘤相关巨噬细胞极化为M2样巨噬细胞，而M2样巨噬细胞反过来又促进肿瘤发生。
Blood Adv. 2021 Jul 27;5(14):2863-2878. doi: 10.1182/bloodadvances.2020003871.
3
SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.SOX11、CD70 和调节性 T 细胞构成侵袭性套细胞淋巴瘤的肿瘤免疫微环境。
Blood. 2021 Dec 2;138(22):2202-2215. doi: 10.1182/blood.2020010527.
4
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.纵向单细胞分析揭示难治性套细胞淋巴瘤中的分子异质性和肿瘤免疫演变。
Nat Commun. 2021 May 17;12(1):2877. doi: 10.1038/s41467-021-22872-z.
5
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.来那度胺在滤泡性淋巴瘤患者体内引发 T 细胞效应功能。
Blood Adv. 2021 Apr 27;5(8):2063-2074. doi: 10.1182/bloodadvances.2020003774.
6
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
7
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.CD163、PD-L1 和 FoxP3 阳性细胞浸润与既定风险因素无关，会对套细胞淋巴瘤患者的预后产生不利影响。
Br J Haematol. 2021 May;193(3):520-531. doi: 10.1111/bjh.17366. Epub 2021 Mar 8.
8
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.利妥昔单抗和奥滨尤妥珠单抗对B细胞受体和NOTCH1信号通路的劫持作用存在差异。
iScience. 2021 Jan 22;24(2):102089. doi: 10.1016/j.isci.2021.102089. eCollection 2021 Feb 19.
9
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.依帕珠单抗针对 DLBCL、FL 和 MCL 患者的恶性 B 细胞具有强大的抗肿瘤活性，无论先前是否接受过 CD20 单克隆抗体治疗。
Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6.
10
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.CD40 诱导的 CLL 耐药中，非经典 NF-κB 对 Bcl-XL 的调控。
Cell Death Differ. 2021 May;28(5):1658-1668. doi: 10.1038/s41418-020-00692-w. Epub 2021 Jan 25.
Zotero 插件